ALEXANDRIA, Va., Feb. 19 -- United States Patent no. 12,227,563, issued on Feb. 18, was assigned to Teijin Pharma Ltd. (Tokyo).
"Anti-IGF-I receptor humanized antibody" was invented by Akira Tanokura (Tokyo), Hirotsugu Kato (Tokyo), Hiroshi Eguchi (Tokyo), Kenichiro Takagi (Tokyo), Satoshi Yamamura (Tokyo), Naoko Namiki (Tokyo), Daisuke Ishikawa (Kikuchi, Japan), Hirofumi Higuchi (Kikuchi, Japan), Tomoyo Takeo (Kikuchi, Japan) and Masayo Ohori (Kikuchi, Japan).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is a humanized antibody that, through IGF-I receptor, increases muscle mass but does not lower the blood glucose level. This humanized antibody: is an anti-IGF-I receptor humanized antibody, a frag...